Compare SRFM & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRFM | TENX |
|---|---|---|
| Founded | 2011 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.0M | 71.1M |
| IPO Year | 2023 | 2001 |
| Metric | SRFM | TENX |
|---|---|---|
| Price | $0.51 | $1.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $3.25 | ★ $29.67 |
| AVG Volume (30 Days) | 1.7M | ★ 7.0M |
| Earning Date | 05-11-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.69 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $106,557,000.00 | N/A |
| Revenue This Year | $25.90 | N/A |
| Revenue Next Year | $20.72 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.61 | $1.31 |
| 52 Week High | $6.17 | $19.40 |
| Indicator | SRFM | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 31.34 | 26.18 |
| Support Level | N/A | $1.31 |
| Resistance Level | $0.75 | $2.43 |
| Average True Range (ATR) | 0.04 | 0.19 |
| MACD | -0.00 | 0.47 |
| Stochastic Oscillator | 5.18 | 37.11 |
Surf Air Mobility Inc is a regional air mobility platform operating commuter airlines in the United States and expanding an on-demand charter marketplace for passengers in the U.S. and globally. It is also focused on developing a proprietary aviation software, aircraft electrification powertrain technology and services to enable electrification across the regional air mobility sector. The company operates in a single reportable segment, Air Mobility. The Air Mobility segment derives revenue from operating scheduled commercial air service flights, which are sold to the public mainly on a per-seat basis; through subsidized EAS revenue awards from the Department of Transportation; and by operating on-demand flights for customers on an ad-hoc, by request basis.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.